adalimumab 40mg solution for injection (Humira)

Advice

Following a full submission

adalimumab (Humira®) is not recommended for use within NHS Scotland for the treatment of severe, active Crohn’s disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

In both induction and maintenance studies in patients with severe active Crohn’s disease, more patients treated with adalimumab achieved and maintained clinical remission than with placebo. However, the manufacturer did not present a sufficiently robust economic case to gain acceptance by the SMC.